MedTrace Logo

Functional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact

NCT06900335 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2025-04-01

No results posted yet for this study

Summary

The goal of this observational study is to explore brain network changes and identify patterns related to hyperphagia, hormonal treatment effects, and cognitive deficits in adults with Prader-Willi Syndrome (PWS). The main questions it aims to answer are:

* How are brain connectivity patterns altered in PWS patients compared to healthy and obese controls?
* How do brain network changes relate to hyperphagia and the response to growth hormone therapy?

Researchers will compare PWS patients to healthy and obese controls to see if there are significant differences in brain network connectivity before and after meals and growth hormone therapy. Ultimately, researchers will try to develop predictive models of treatment outcomes using AI and machine learning.

Conditions

Interventions

DRUG

GH treatment (Somatropin)

Treatment with Somatropin (recombinant GH), with doses starting from 0.2 mg/day and adjusted as necessary.

BEHAVIORAL

Eating

Allowing patients to break fasting.

Sponsors & Collaborators

  • Corporacion Parc Tauli

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-03-15
Completion
2025-03-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06900335 on ClinicalTrials.gov